Ignacio García-Ribas

Suggest Changes
Learn More
PURPOSE There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), with no standard of care. A randomized phase II trial showed(More)
BACKGROUND Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through(More)
Iniparib is an investigational agent with antitumor activity of controversial mechanism of action. Two previous trials in advanced triple-negative breast cancer (TNBC) in combination with gemcitabine(More)
580 Background: GEP of primary breast tumors can be useful in selecting specific chemotherapy regimens based on their probabilities of response. METHODS A neoadjuvant phase II trial for stage(More)